<DOC>
	<DOCNO>NCT01346878</DOCNO>
	<brief_summary>This study aim analyze association baseline detection resistance mutation Ultra deep Sequencing ( UDS ) virological outcome salvage antiretroviral therapy , comparison conventional genotypic resistance test . Based data generate study , new resistance interpretation tool algorithms develop improve prediction antiretroviral therapy outcome . The final aim study improve clinical care HIV-1-infected patient incorporation improve new antiretroviral resistance test clinical practice .</brief_summary>
	<brief_title>Antiretroviral Resistance Detection Ultrasensitive Pyrosequencing HIV-1 Genome Virological Response Antiretroviral Rescue Treatment</brief_title>
	<detailed_description>Antiretroviral resistance test essential tool clinical management Human Immunodeficiency Virus ( HIV-1 ) -infected person HIV surveillance community . In absence appropriate treatment , HIV-1 infection lead toward collapse immune system death HIV-1-infected person . Adequate antiretroviral treatment usually reverse process . Nevertheless , HIV-1 easily develop treatment resistance accumulation mutation genome . This cause treatment failure , requirement increasingly complex , toxic expensive treatment . Resistant virus transmit person . More 10 % HIV-1-positive person Spain become infected virus already resistant least one antiretroviral drug . Antiretroviral treatment regimen design basis drug resistance information efficacious , effective efficient . In spite clinical relevance , however , conventional resistance test insensitive underestimate antiretroviral resistance . By mean new ultrasensitive resistance test possible detect resistant virus minority population remain undetected conventional genotypic test . Ultrasensitive resistance test thus double triple number patient antiretroviral resistance detect . It important emphasize detection minority resistant mutant antiretroviral na√Øve patient increase triple risk virological failure . The clinical impact detect minority resistant variant treatment-experienced patient therapeutic failure remain unknown . Recently develop technique parallel emulsion sequence thousand amplicon clone ( Ultra deep Sequencing ( UDS ) , Roche Diagnostics/454 Life Sciences ) increase sensibility detect polymorphisms mutation highly variable genome HIV-1 several order magnitude . In addition , technique allows stablishing genetic linkage mutation polymorphisms thousand HIV-1 clonal sequence every patient point follow-up . This generate unprecedented opportunity characterize nature HIV-1 variability physiopathology antiretroviral resistance depth . Ultrasensitive resistance test hold promise improve clinical management HIV-1 seropositive patient , avoid unnecessary toxicity , improve epidemiological estimation antiretroviral resistance , improve knowledge pathogenesis HIV-1 infection antiretroviral resistance , improve cost-efficiency HIV-related pharmaceutical cost . This study aim analyze association baseline detection resistance mutation UDS virological outcome salvage antiretroviral therapy , comparison conventional genotypic resistance test . Based data generate study , new resistance interpretation tool algorithms develop improve prediction antiretroviral therapy outcome . The final aim study improve clinical care HIV-1-infected patient incorporation improve new antiretroviral resistance test clinical practice .</detailed_description>
	<criteria>1 . Adults 18 year old , HIV + , distribute one follow 3 treatment group : PI GROUP : prior virologic failure HAART regimen include PI ( ritonavir boost ) , second consecutive start HAART regimen include PI boost ritonavir + 2 NRTIs . The 6 month prior start second HAART regimen , consider baseline . NNRTI GROUP : Virologic failure HAART regimen include 1 NNRTI 2 NRTIs , begin , consecutive , rescue HAART regimen etravirine , combination drug . The 6 month start rescue HAART regimen etravirine , consider baseline . II GROUP : Virologic failure prior HAART initiation rescue HAART include raltegravir , combination drug . The 6 month start rescue HAART raltegravir consider baseline . 2 . Sample 1 mL plasma available pyrosequencing start rescue HAART . 3 . Viral load HIV1 &gt; 5,000 copy / mL time obtain plasma sample . 4 . Any CD4 + count . 5 . Availability clinical followup , viral load HIV1 quarterly CD4 count least 48 week initiation rescue HAART . 6 . Good adherence therapy . 7 . The investigation period event start study . 1 . HIV2 infection HIV1 subtype nonB . 2 . Poor adherence therapy . 3 . Lack adequate clinical laboratory follow . 4 . Noncompliance patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ultra deep sequencing</keyword>
	<keyword>Virological failure</keyword>
	<keyword>Salvage antiretroviral therapy</keyword>
</DOC>